Home : Unsafe Drugs : Byetta : Newsfeeds

Byetta - Newsfeeds

Roche dumps taspo as analysts read last rites
Taspo's trouble could be a boon to other new drugs in development for diabetes, including Bydureon, the troubled next-gen therapy to Byetta. For analysts, Roche's decision leaves the experimental drug in limbo, for now. "The key is whether Ipsen will ...
Roche Said to Return Diabetes Drug Rights to Ipsen
A failure of the drug would benefit competing products, including Byetta from Eli Lilly & Co. and Amylin Pharmaceutical Inc., a weekly version of Byetta called Bydureon, and Novo Nordisk A/S’s Victoza. In one study, between 40 and 47 percent of diabetes ...
NICE Issues Its Final Appraisal Determination (FAD) On The Use Of Victoza(R) (liraglutide) For ...
Statutory funding direction does not apply to NICE clinical guidelines such as those containing Byetta ® and Januvia ®, but only to technology appraisals such as this one. Liraglutide 1.2 mg daily in dual therapy ...
Roche halts Taspoglutide dosing in final studies
who sell the rival medication Byetta. Novo Nordisk A/S of Copenhagen received U.S. approval for its competing drug Victoza in January. In June, Roche said it was delaying plans to seek approval of taspoglutide next ...
Roche Stops Giving Diabetes Drug in Final Trial Over Nausea, Side Effects
s Byetta and Novo Nordisk A/S’s Victoza.
Once-weekly Exenatide vs. Sitagliptin or Pioglitazone for Type 2 Diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists such as the currently available formulation of exenatide (Byetta) require once- or twice-daily injections; a once-weekly subcutaneous formulation of exenatide is ...
Barclays Maintains an 'Overweight' Rating on Amylin Pharmaceuticals (AMLN); TRx Share Continues ...
Byetta TRx and NRx, and Victoza NRx with an increase in Victoza TRx. Byetta market share within the GLP-1 category continued its decreasing trend while TRx share for GLP-1 drugs in the diabetes category continued to ...
Amylin shares dip on diabetes drug study results
The drug is a once-weekly version of the twice-daily injectable drug Byetta, and a key concern for the market is Bydureon's prospects against Novo Nordisk's once-daily drug Victoza, which received FDA approval in January ...
Amylin shares rise ahead of diabetes meeting
The drug is a longer-lasting version of Amylin and Lilly's Byetta diabetes drug. It was developed with technology from Alkermes Inc ( ALKS.O ) that releases the drug at a controlled rate. Similar drugs are being ...
Amylin shares fall after new Bydureon data hits
Bydureon, which is injected once a week and is a longer-lasting version of the companies' Byetta drug, also known as exenatide, belongs to the GLP-1 class of drugs that stimulate insulin production in order to regulate ...
Amylin drug trial success is mixed
Much is riding on the success of Bydureon, a weekly version of Amylin’s Byetta that has been used by more than 1 million patients who must inject the drug daily. Byetta was a breakthrough medication that boosted ...
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy ...
BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA ® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in approximately 60 countries worldwide to ...
A Drop on Bad News, but It Was a Long Shot Anyway
Bydureon, Amylin Pharmaceuticals (Nasdaq: AMLN ) and Eli Lilly 's (NYSE: LLY ) once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials called ...
Biotech reports record financial results for 2010 first ...
and Alkermes, to conduct additional studies on the drug exenatide LAR, or Bydureon, a once-weekly version of the twice-daily Byetta injection. Strong fourth quarter financials were the driving force of Alexion's pop in its shares (up 10 percent in ...
Redpoint: Sitting in the Sweet Spot
Given the obvious validation of this pathway by blockbuster drugs such as Byetta and Januvia, Redpoint has received significant interest from pharmaceutical partners looking to collaborate through an early-stage discovery program on TRPm5.
FDA approved diabetes drug despite hints at cancer risk
She noted that Victoza has one advantage over its only other competitor in this class of drugs, Byetta. Byetta is administered as a twice-daily injection, whereas Victoza is a once-daily injection, Mahoney noted. The agency is requiring that a ...
Biotech Posts Strong First Quarter Gain
and Alkermes, to conduct additional studies on the drug exenatide LAR, or Bydureon, a once-weekly version of the twice-daily Byetta injection. Strong fourth quarter financials were the driving force of Alexion's pop in its shares (up 10 percent in ...
Takeda, Amylin to co-develop obesity drugs
Amylin, maker of the diabetes drug Byetta, could also receive development and sales-based milestones worth more than $ 1 billion if the compounds in the agreement were successful, the companies said in a statement. The agreement includes Amylin's ...
Novo Nordisk CEO hopeful on U.S. Victoza approval
Victoza and Byetta both belong to the GLP-1 class of drugs that stimulate insulin release when glucose levels become too high. Novo's drug was approved in Europe in July and has been launched in Germany, Britain and Denmark, with other markets set to ...
Reuters Summit-UPDATE 1-Novo CEO hopeful on Victoza approval
... heads the world's biggest producer of insulin, also said the drug was achieving rapid uptake in Europe and was set to overtake Eli Lilly's and Amylin Pharmaceuticals Inc's rival Byetta treatment in Germany by the end of the year. The delays ...
Want to contact a Byetta lawyer in Washington, DC? ...Get a free case evaluation from one of our Byetta lawyers in Washington, DC now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages:   1   2   Next

Need A Byetta Attorney?

First Name Last Name Email Address State
Was Your Health Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Want to contact a Byetta lawyer in Washington, DC? ...Get a free case evaluation from one of our Byetta lawyers in Washington, DC now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Byetta Case - Submit Your Information Below

Do you need legal assistance with your Byetta case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * Unsafe Drugs: Byetta Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.